IP Library › Granted Patent US 12,310,950
Granted Patent B2
US 12,310,950 · App. 17/992,859 · Granted May 27, 2025

Formulations of pyrrolopyridine-aniline compounds

Inventors: Christopher Powala (Wayne, PA); Elaine Morefield (Boston, MA); Charles Rodney Greenaway Evans (Godalming, GB); Cameron Robert Stevenson (Guildford, GB); Brendan Philip Brady (Guildford, GB)
Assignee: NFLECTION THERAPEUTICS, INC.
A61K31/437A61K9/06A61K31/381A61K47/10A61K47/38A61P17/00B64D1/12B64U2101/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,950
App. No.
17/992,859
Granted
May 27, 2025
Kind
B2
Abstract

Provided herein are topical formulations including a compound of formula (I) and methods of using these topical formulations for the treatment of skin diseases, wherein the topical formulations include non-aqueous gel, aqueous gel, and emulsion-based formulations; and the compound of formula (I) is represented by wherein R 1 , R 2 , R 2a , R 3 , R 3a , and R 3b are as defined and described herein.

Claims (92)

1. A gel formulation, comprising:

a) a compound represented by formula:

or a pharmaceutically acceptable salt thereof;

b) a polyethylene glycol, an antioxidant, and optionally a preservative,

wherein

the polyethylene glycol is PEG-400,

the antioxidant is butylated hydroxytoluene, butylated hydroxyanisole, an ascorbyl ester, or combination thereof;

the preservative, when present, is benzyl alcohol, phenoxyethanol, potassium sorbate, of combinations thereof;

c) one or more organic solvents which is 2-(2-ethoxyethoxy)ethanol; and

d) a gelling agent that is hydroxypropyl cellulose,

wherein:

the polyethylene glycol is present in an amount of at least about 30% by weight;

the gelling agent has an average molecular weight of from about 80,000 Da to about 1,700,000 Da;

the gel formulation has a pH value of no more than about 7; and

water, when present, is no more than about 5% by weight.

2. The gel formulation of claim 1 , wherein the gel formulation has a viscosity of from about 10,000 to about 200,000 cps, from about 15,000 to about 200,000 cps, from about 20,000 to about 200,000 cps, from about 25,000 to about 200,000 cps, from about 10,000 to about 100,000 cps, from about 15,000 to about 100,000 cps, from about 20,000 to about 100,000 cps, from about 25,000 to about 100,000 cps, from about 10,000 to about 50,000 cps, from about 15,000 to about 50,000 cps, from about 20,000 to about 50,000 cps, from about 25,000 to about 50,000 cps, from about 10,000 to about 40,000 cps, from about 15,000 to about 40,000 cps, from about 20,000 to about 40,000 cps, or from about 25,000 to about 40,000 cps.

3. The gel formulation of claim 2 , wherein the gel formulation has a viscosity of from about 15,000 to about 50,000 cps.

4. The gel formulation of claim 1 , wherein PEG-400 is present in an amount of from about 50% to about 60% by weight, based on a total weight of the formulation.

5. The gel formulation of claim 1 , wherein the 2-(2-ethoxyethoxy) ethanol is present in an amount of from about 40% to about 50% by weight, based on a total weight of the formulation.

6. The gel formulation of claim 1 , wherein the antioxidant is butylated hydroxytoluene in an amount of from about 0.1% to about 0.5%, from about 0.1% to about 0.4%, or from about 0.1% to about 0.3% by weight, based on a total weight of the formulation.

7. The gel formulation of claim 6 , wherein butylated hydroxytoluene is present in an amount of about 0.2% by weight, based on a total weight of the formulation.

8. The gel formulation of claim 1 , wherein the antioxidant is an ascorbyl ester comprising ascorbyl palmitate, which is present in an amount of from about 0.01% to about 0.1% by weight, based on a total weight of the formulation.

9. The gel formulation of claim 1 , wherein the preservative, when present, is phenoxyethanol in an amount of from about 0.5% to about 5%, from about 0.5% to about 4%, from about 0.5% to about 3%, or from about 0.5% to about 2% by weight, based on a total weight of the formulation.

10. The gel formulation of claim 9 , wherein phenoxyethanol is present in an amount of about 1% by weight, based on a total weight of the formulation.

11. The gel formulation of claim 1 , wherein the preservative, when present, is potassium sorbate in an amount of from about 0.05% to about 0.5%, from about 0.05% to about 0.4%, from about 0.05% to about 0.3%, or from about 0.05% to about 0.2% by weight, based on a total weight of the formulation.

12. The gel formulation of claim 11 , wherein potassium sorbate is present in an amount of about 0.1% by weight, based on a total weight of the formulation.

13. The gel formulation of claim 1 , wherein PEG-400 is a super refined PEG-400; and/or 2-(2-ethoxyethoxy) ethanol has a purity of greater than about 99.90%.

14. The gel formulation of claim 1 , wherein the hydroxypropyl cellulose has an average molecular weight of from about 850,000 Da to about 1,150,000 Da.

15. The gel formulation of claim 1 , wherein the hydroxypropyl cellulose has an average molecular weight of about 1,150,000 Da and is present in an amount of from about 0.5% to about 2% by weight, based on a total weight of the formulation.

16. The gel formulation of claim 1 , wherein the compound of formula (Ib) is present in an amount of from about 0.1% to about 3% by weight, based on a total weight of the formulation.

17. A gel formulation, comprising:

a) a compound represented by the formula:

 or a pharmaceutically acceptable salt thereof;

b) PEG-400, 2-(2-ethoxyethoxy) ethanol, butylated hydroxytoluene, and potassium sorbate; and

c) a hydroxypropyl cellulose having an average molecular weight of from about 850,000 Da to about 1,150,000 Da,

wherein the gel formulation has a pH value of no more than about 7.

18. A gel formulation, comprising:

a) a compound represented by the formula:

 or a pharmaceutically acceptable salt thereof,

b) PEG-400, 2-(2-ethoxyethoxy) ethanol, butylated hydroxytoluene, and phenoxyethanol; and

c) a hydroxypropyl cellulose having an average molecular weight of from about 850,000 Da to about 1,150,000 Da,

wherein the gel formulation has a pH value of no more than about 7.

19. The gel formulation of claim 18 , wherein the gel formulation has a viscosity of from about 15,000 to about 50,000 cps.

20. The gel formulation of claim 17 , comprising:

a) about 0.5% by weight of the compound;

b) from about 50% to about 55% by weight of the PEG-400;

c) about 45% by weight of the 2-(2-ethoxyethoxy) ethanol;

d) about 0.2% by weight of the butylated hydroxytoluene;

e) about 0.1% by weight of the potassium sorbate;

f) from about 0.5% to about 2% by weight of the hydroxypropyl cellulose having an average molecular weight of about 1,150,000 Da; and

g) citric acid, and

h) optionally from about 0.001% to about 0.05% by weight of one or more dyes, wherein the total weight of a) to h) is 100%; and the citric acid is a solution in the PEG-400 or the 2-(2-ethoxyethoxy) ethanol to adjust a pH.

21. The gel formulation of claim 17 , comprising:

a) about 1.5% by weight of the compound;

b) from about 50% to about 53% by weight of the PEG-400;

c) about 45% by weight of the 2-(2-ethoxyethoxy) ethanol;

d) about 0.2% by weight of the butylated hydroxytoluene;

e) about 0.1% by weight of the potassium sorbate;

f) from about 0.5% to about 2% by weight of the hydroxypropyl cellulose having an average molecular weight of about 1,150,000 Da; and

g) citric acid,

wherein the total weight of a) to g) is 100%; and the citric acid is a solution in the PEG-400 or the 2-(2-ethoxyethoxy) ethanol to adjust a pH.

22. The gel formulation of claim 18 , comprising:

a) from about 0.005% to about 3% by weight of the compound;

b) from about 50% to about 55% by weight of the PEG-400;

c) from about 40% to about 50% by weight of the 2-(2-ethoxyethoxy) ethanol;

d) from about 0.1% to about 0.3% by weight of the butylated hydroxytoluene;

e) from about 0.5% to about 2% by weight of the phenoxyethanol;

f) optionally from about 1% to about 3% PEG-1500;

g) from about 0.5% to about 2% by weight of the hydroxypropyl cellulose having an average molecular weight of about 1,150,000 Da;

h) citric acid; and

i) optionally from about 0.001% to about 0.05% by weight of one or more dyes,

wherein the total weight of a) to i) is 100%; and the citric acid is a solution in the PEG-400 or the 2-(2-ethoxyethoxy) ethanol to adjust a pH.

23. The gel formulation of claim 18 , comprising:

a) about 0.5% by weight of the compound;

b) about 52% by weight of the PEG-400;

c) about 45% by weight of the 2-(2-ethoxyethoxy) ethanol;

d) about 0.2% by weight of the butylated hydroxytoluene;

e) about 1% by weight of the phenoxyethanol;

f) about 1% by weight of the hydroxypropyl cellulose having an average molecular weight of about 1,150,000 Da;

g) citric acid; and

h) optionally about 0.02% by weight of one or more dyes,

wherein the total weight of a) to h) is 100%; and the citric acid is a solution in the PEG-400 or the 2-(2-ethoxyethoxy) ethanol to adjust a pH.

24. The gel formulation of claim 18 , comprising:

a) about 1.5% by weight of the compound;

b) about 51% by weight of the PEG-400;

c) about 45% by weight of the 2-(2-ethoxyethoxy) ethanol;

d) about 0.2% by weight of the butylated hydroxytoluene;

e) about 1% by weight of the phenoxyethanol;

f) about 1% by weight of the hydroxypropyl cellulose having an average molecular weight of about 1,150,000 Da; and

g) citric acid,

wherein the total weight of a) to g) is 100%; and the citric acid is a solution in the PEG-400 or the 2-(2-ethoxyethoxy) ethanol to adjust a pH.

25. A method of treating a skin disorder comprising administering a gel formulation of claim 1 , wherein the skin disorder is a MEK-inhibitor responsive dermal disorder or a MEK-mediated dermal disorder, a birthmark, or a skin cancer.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND PCT APPLICATION IN THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 67351 FRAME: 567. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jul 30, 2024
From: EVANS, CHARLES RODNEY GREENAWAY; STEVENSON, CAMERON ROBERT; BRADY, BRENDAN PHILIP
To: MEDPHARM LTD
Reel/Frame 068219/0740 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PCT APPLICATION NUMBER IN THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 67351 FRAME: 325. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jul 30, 2024
From: POWALA, CHRISTOPHER; MOREFIELD, ELAINE
To: NFLECTION THERAPEUTICS, INC.
Reel/Frame 068220/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2024
From: POWALA, CHRISTOPHER; MOREFIELD, ELAINE
To: NFLECTION THERAPEUTICS, INC.
Reel/Frame 067351/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2024
From: EVANS, CHARLES RODNEY GREENAWAY; STEVENSON, CAMERON ROBERT; BRADY, BRENDAN PHILIP
To: MEDPHARM LTD
Reel/Frame 067351/0567 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2024
From: MEDPHARM LTD
To: NFLECTION THERAPEUTICS, INC.
Reel/Frame 067351/0694 →
Continuity (2)
Provisional Application 63282395 · Nov 23, 2021
Related Publication 20230255945A1 · Aug 17, 2023
References Cited (41)
US 7803839B2 · Aay et al. · 2010 [cited by applicant]
US 7915250B2 · Aay et al. · 2011 [cited by applicant]
US 8211921B2 · Blake et al. · 2012 [cited by applicant]
US 8252838B2 · Kisak et al. · 2012 [cited by applicant]
US 8470821B2 · Ibrahim et al. · 2013 [cited by applicant]
US 11161845B2 · Kincaid et al. · 2021 [cited by applicant]
US 20050202001A1 · Koo et al. · 2005 [cited by applicant]
US 20090082328A1 · Li et al. · 2009 [cited by applicant]
US 20100075947A1 · Aftab et al. · 2010 [cited by applicant]
US 20100215579A1 · Kung et al. · 2010 [cited by applicant]
US 20140213598A1 · Liu et al. · 2014 [cited by applicant]
US 20150023915A1 · Morrison et al. · 2015 [cited by applicant]
US 20150335644A1 · Seykora · 2015 [cited by applicant]
US 20180256570A1 · Peterson et al. · 2018 [cited by applicant]
US 20210275495A1 · Vivier · 2021 [cited by applicant]
US 20220033399A1 · Kincaid et al. · 2022 [cited by applicant]
US 20220087989A1 · Tsai et al. · 2022 [cited by applicant]
US 20220110862A1 · Powala et al. · 2022 [cited by applicant]
US 20220204486A1 · Kincaid et al. · 2022 [cited by applicant]
US 20230013227A1 · Kincaid et al. · 2023 [cited by applicant]
WO WO1999001421A1 · 1999 [cited by applicant]
WO WO2000042029A1 · 2000 [cited by applicant]
WO WO2007002433A1 · 2007 [cited by applicant]
WO WO2007088345A1 · 2007 [cited by applicant]
WO WO2008021389A2 · 2008 [cited by applicant]
WO WO2008067481A1 · 2008 [cited by applicant]
WO WO2018213810A1 · 2018 [cited by applicant]
WO WO2019139970A1 · 2019 [cited by applicant]
WO WO2020106303A1 · 2020 [cited by applicant]
WO WO2020106304A1 · 2020 [cited by applicant]
WO WO2020106305A1 · 2020 [cited by applicant]
WO WO2020106307A1 · 2020 [cited by applicant]
Akinleye et al., “MEK and the Inhibitors: From Bench to Bedside,” Journal of Hematology & Oncology, 2013, 6(27), 11 pages. [cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2018/033547, mailed Aug. 9, 2018, 10 pages. [cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2019/000067, mailed Apr. 24, 2020, 11 pages. [cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2019/000066, mailed Feb. 7, 2020, 16 pages. [cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2019/000065, mailed Apr. 24, 2020, 10 pages. [cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2019/000069, mailed Mar. 20, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion for International application No. PCT/US2022/050794, mailed Apr. 24, 2023, 13 pages. [cited by applicant]
PUBCHEM-CID; 131273078, Create Date; Oct. 9, 2017, pp. 1-7, p. 2, structure. [cited by applicant]
PUBCHEM-CID; 69072648, Create Date; Nov. 30, 2012, pp. 1-9, p. 2, structure. [cited by applicant]
Cited By (1)
US 12,649,742